Lindsey Owens
Research coordinator and doctoral trainee in medical/clinical psychology; psychedelic-assisted therapy researcher
Data updated
Research Footprint
Lindsey Owens appears in 5 tracked papers (2018–2024), most studied alongside Psilocybin and Ayahuasca, across Alcohol Use Disorder (AUD), Substance Use Disorders (SUD) and Interpersonal Functioning & Social Connectedness.
Most-cited paper: Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder (644 citations).
Frequent co-authors: Michael Bogenschutz, Susan Mennenga and Samantha Podrebarac.
Background & Research
Lindsey T. Owens appears to be a psychedelic research coordinator and trainee in medical/clinical psychology with prior work at NYU Langone and later affiliation with the University of Alabama at Birmingham. Public bios describe her as a researcher focused on psychedelic-assisted therapeutics, trauma-informed care, self-compassion, and spiritual/exceptional experiences, and as someone involved in psilocybin studies for alcohol use disorder and smoking cessation.
Key Impact
She is notable for coauthoring and supporting several key psilocybin-assisted psychotherapy studies on alcohol use disorder, including clinical, qualitative, and case-report papers.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Lindsey Owens is associated with.
University of Alabama at Birmingham
Major research university and academic medical center in Birmingham, Alabama. A key site in the first federally funded psilocybin trial in 50 years — a NIH/NIDA-funded multisite study on psilocybin for smoking cessation led by Dr. Peter Hendricks, alongside Johns Hopkins and NYU.
View stakeholder →NYU Langone Health
Home to the NYU Langone Center for Psychedelic Medicine, one of the world's leading academic institutions in psychedelic research. Has conducted landmark psilocybin trials for smoking cessation, alcohol use disorder, and depression in cancer patients, spearheaded by Dr. Michael Bogenschutz and colleagues.
View stakeholder →